Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

Core Insights - Instil Bio, Inc. has received FDA clearance for the Investigational New Drug (IND) application for AXN-2510, a bispecific antibody targeting PD-L1 and VEGF, aimed at treating multiple solid tumors [1][3] - The company plans to initiate a phase 1 trial of AXN-2510 as a monotherapy for patients with relapsed/refractory solid tumors before the end of 2025 [2] - Initial safety and efficacy results from a phase 2 trial of AXN-2510 in combination with chemotherapy for first-line non-small cell lung cancer (NSCLC) in China are expected to be shared in the second half of 2025 [1][2] Company Overview - Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies [3] - The lead asset, AXN-2510, is positioned as a differentiated treatment option for various solid tumors [3]